1. Home
  2. GERN vs PD Comparison

GERN vs PD Comparison

Compare GERN & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo PagerDuty Inc.

PD

PagerDuty Inc.

SELL

Current Price

$17.49

Market Cap

1.1B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
GERN
PD
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
GERN
PD
Price
$1.10
$17.49
Analyst Decision
Buy
Hold
Analyst Count
5
9
Target Price
$4.25
★ $12.64
AVG Volume (30 Days)
★ 5.9M
1.5M
Earning Date
11-04-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
51.85
★ 416.95
EPS
N/A
★ 0.19
Revenue
$1,065,000.00
★ $492,546,000.00
Revenue This Year
$28.49
$0.35
Revenue Next Year
$44.73
$2.03
P/E Ratio
★ N/A
$90.42
Revenue Growth
N/A
★ 5.36
52 Week Low
$1.04
$5.70
52 Week High
$2.01
$17.55

Technical Indicators

Market Signals
Indicator
GERN
PD
Relative Strength Index (RSI) 32.01 69.66
Support Level $1.08 $6.08
Resistance Level $1.26 $17.55
Average True Range (ATR) 0.05 0.58
MACD -0.00 0.03
Stochastic Oscillator 8.33 93.39

Price Performance

Historical Comparison
GERN
PD

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.

Share on Social Networks: